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ABSTRACT
Introduction: The aim of this study was to
investigate the frequency and duration of missed
hospital appointments (MHAs) in a consecutive
cohort of patients treated with ranibizumab for
neovascular age-related macular degeneration
(nAMD) and to assess their impact on outcomes
of therapy in a real-world clinical setting.
Methods: Retrospective, cross-sectional study
of consecutive patients attending medical
retina clinics for nAMD treatment with
ranibizumab.
Results: Seventy-eight eyes of 78 patients met
the inclusion criteria for data analysis. Mean age
was 78 years with mean follow-up of 27 months.
Mean visual acuity (VA) was 52 ± 16 letters at
baseline, 56 ± 17 letters at year 1 and 58 ± 16
letters at year 2. At the end of the second year,
90% of the patients had lost\15 letters, 26% had
gained C15 letters and 10% had lost C15 letters.
Nineteen patients had at least one MHA (24%)
over 2 years. There were 26 MHA episodes in total
leading to a median duration of 79 days (range
35–159) between attended hospital visits. None of
these MHAs occurred during the first 3 months
after treatment initiation. Mean VA and central
retinal thickness difference between 2 years and
baseline for the MHA group was not statistically
different compared with the non-MHA group.
Conclusions: Our data suggest that MHA may
be a relatively common occurrence in AMD
treatment clinics, but good outcomes of
treatment can be achieved over 2 years despite
missed hospital visits if patients are reviewed on
average six times in the first year after an initial
loading phase of three injections and nine times
in the second year of treatment.
Keywords: Age-related macular degeneration;
Missed appointment; Ranibizumab
INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of blindness among elderly
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patients in developed countries [1, 2]. While the
neovascular form of AMD (nAMD)
characterized by choroidal neovascularization
(CNV) comprises approximately 10% of the
disease, it is responsible for over 90% of cases
of severe visual loss [3–5]. Over the last few
years, introduction of anti-vascular endothelial
growth factor (anti-VEGF) therapy, such as
ranibizumab, has revolutionized the
management of nAMD. The latter has been
approved for use on the basis of phase III
clinical trials with monthly follow-up and
treatment over 24 months [6, 7]. Further
research trialed anti-VEGF regimens of varying
dosage and frequency of therapy
administration, in an attempt to maximize
visual acuity (VA) outcomes while minimizing
treatment burden [8–14]. In studies reporting
sustained improvements in vision, patients had
very frequent follow-ups with monthly
ophthalmic examinations. However in clinical
practice, patients with nAMD often have
significant coexisting medical conditions,
which may impact on their ability to attend
their regular AMD clinic appointments [6, 10].
It is also important to note that clinical trials
often exclude patients who may not comply
with mandated study visits and may only
include patients who are able to attend
monthly follow-up visits [12]. This may mean
that in practice, the intensive follow-up and
treatment paradigms used in clinical trials may
be difficult to implement. If this is indeed a
significant problem, then it has the potential to
impact on the outcomes of therapy in clinical
practice, as less intensive follow-up can result in
poorer outcomes of treatment [15, 16].
The aim of this study was to report the
proportion of patients with missed hospital
appointments (MHAs) for nAMD assessment in
a consecutive cohort of patients treated with
ranibizumab and to report the duration of such
MHAs. An additional aim was to report long-
term functional and structural outcomes in this
patient group and compare them with the
subgroup of consecutively treated patients
without MHAs, thus assessing the potential
impact of MHAs on outcomes of therapy in a
real-world clinical setting.
METHODS
This was a retrospective cross-sectional study.
Consecutive patients with nAMD treated in
AMD treatment clinics of Moorfields Eye
Hospital were evaluated. The inclusion criteria
consisted of treatment-naı¨ve patients with all
types of CNV secondary to nAMD managed
with intravitreous ranibizumab therapy using a
pro re nata (PRN) regimen and follow-up period
of at least 24 months. The exclusion criteria
included eyes with any prior treatment for
nAMD (including laser photocoagulation,
verteporfin photodynamic therapy and
intravitreal pegaptanib sodium, ranibizumab
or bevacizumab) and the presence of other
retinal disease likely to compromise VA.
Patient records were reviewed and the
following data were collected: age, best-
corrected VA assessed with the use of Early
Treatment Diabetic Retinopathy Study (ETDRS)
charts using the most up-to-date distance
correction at each visit, follow-up period,
analysis of baseline fluorescein angiogram
(FFA) to establish CNV lesion type and lesion
size, spectral-domain optical coherence
tomography (OCT)-derived central retinal
thickness (CRT) and the presence, number and
duration of MHAs. MHA duration was defined
as the interval between the appointment before
the MHA and the next appointment at which
the patient attended (giving the interval
between attended hospital visits either side of
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the missed visit). Data were analyzed with
frequency and descriptive statistics. Mean
values were compared using independent
samples t test. A p value \0.05 was considered
to be statistically significant. All statistics were
calculated using SPSS software version 17.0 for
Windows (SPSS, Inc, Chicago, Illinois, USA).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
During the interval chosen for the study, 78
eyes of 78 patients met the inclusion criteria for
data analysis. The mean age was 78 years (range
52–93 years) and the mean follow-up was
27 months (range 24–38 months). There were
43 women (55%) and all 78 patients were
Caucasian. Mean VA was 52 ± 16 letters at
baseline, 56 ± 17 letters at year 1 and 58 ± 16
letters at year 2. At the end of the second year,
90% of the patients had lost \15 letters, 26%
had gained C15 letters and 10% had lost C15
letters. Mean CRT was 311 ± 87 lm at baseline,
273 ± 72 lm at year 1 and 250 ± 68 lm at year
2. Mean number of injections was 6.7 (range
3–12) in the first year and 4.9 (range 0–12) in
the second year. Mean number of hospital visits
was 9.4 (range 5–12) in the first year and 8.9
(range 3–12) in the second year. Nineteen
patients had at least one MHA (24%). Two
patients had three MHAs, 3 patients had two
MHAs and 14 patients had one MHA. There
were 26 MHA episodes in total with a median
duration of 79 days (range 35–159). None of
these MHAs occurred during the first 3 months
after treatment initiation. Table 1 summarizes
baseline demographics, baseline lesion size and
subtypes for the two groups. Table 2 displays
the treatment-related metrics and Table 3
summarizes the outcomes of ranibizumab
therapy. There was no statistically significant
difference between the two groups regarding
baseline age, baseline VA, baseline CRT and
baseline lesion size. In addition, the two groups
were similar in terms of baseline lesion type
(Table 1). Mean VA and CRT difference between
2 years and baseline for the MHA group was not
statistically different compared with the non-
MHA group (p = 0.981, p = 0.605, respectively)
(Figs. 1 and 2).
Table 1 Baseline demographics, lesion size and subtypes




























Minimally classic 7% 11%
MHAs missed hospital appointments
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DISCUSSION
The management of nAMD has been
transformed by the introduction of anti-VEGF
agents delivered by intravitreous injection. The
licensed therapy, ranibizumab, has been
brought to market on the basis of positive
results of phase III randomized, controlled
trials in which elderly patients with nAMD
were seen at monthly intervals over 24 months
[6, 7]. Other clinical trials with quarterly
hospital visits did not lead to sustained
improvements in vision [15, 16]. Concerns
remain regarding long-term outcomes of
therapy with ranibizumab and how well
outcomes in clinical practice can replicate
those seen in clinical trials [10, 17].
Furthermore, according to the 1-year results
from the IVAN trial (ISRCTN.com #
ISRCTN92166560), 35% of patients had at least
one MHA [18]. These data indicate that despite
the need for a strict follow-up, there are many
co-existing factors that could compromise
patient compliance and therefore also
potentially impinge on treatment outcomes.
The need for intensive monthly follow-up
over 24 months should be balanced against the
pragmatism of offering this therapy to an elderly
cohort of patients who may not be able to
comply with such strict follow-up in view of
other co-morbidities and other factors. Despite
the importance of MHAs in this context and the
potential of MHAs to impact on long-term
outcomes of therapy for nAMD, to our
knowledge there have been no reports of both
the incidence of MHAs and the impact of such
MHAs on the long-term outcomes of


















5 ± 3 4 ± 2 p = 0.083
Overall 12 ± 5 10 ± 4 p = 0.066
Hospital visits
during the 1st year
(mean ± SD)
9 ± 2 9 ± 2 p = 0.849
Hospital visits
during the 2nd
year (mean ± SD)
9 ± 2 9 ± 2 p = 0.516
Overall 18 ± 3 18 ± 4 p = 0.649
MHAs missed hospital appointments
Table 3 Outcomes of ranibizumab therapy
Patients without MHA Patients with MHA Statistical signiﬁcance
Baseline VA (ETDRS letters, mean ± SD) 53.6 ± 15.2 45.5 ± 15.8 p = 0.053
1-year VA (ETDRS letters, mean ± SD) 57 ± 16.5 53 ± 19.4 p = 0.381
2-year VA (ETDRS letters, mean ± SD) 59.3 ± 14.1 52.2 ± 20.7 p = 0.188
Baseline CRT (lm, mean ± SD) 321.1 ± 87.3 272.5 ± 77.8 p = 0.055
1-year CRT (lm, mean ± SD) 281.1 ± 74.6 245.4 ± 54.6 p = 0.080
2-year CRT (lm, mean ± SD) 257 ± 72 219.7 ± 41.6 p = 0.092
MHAs missed hospital appointments, VA visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, CRT central
retinal thickness
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ranibizumab therapy. In this study we found
that although MHAs were not uncommon in
patients who had been undergoing ranibizumab
therapy over a minimum of 24 months
occurring in 24% of patients, there was no
significant impact on the outcomes of
treatment when compared with a group of
consecutively treated patients without MHAs
over the same period. We found that median
duration of MHAs was less than 3 months
(78.5 days). This may explain why no
differences were seen in the outcomes of
treatment in the groups with or without
MHAs. Furthermore, over 2 years, there were a
similar number of hospital visits and
ranibizumab injections in both groups
suggesting that when an MHA occurred, a new
clinic appointment was made relatively rapidly,
reducing the review-free interval and potentially
preventing vision loss. This work suggests that
good treatment outcomes with ranibizumab can
be achieved with nine hospital visits in the first
year and nine hospital visits in the second year.
In the first year this would mean a hospital visit
on average every 7 weeks after the initial loading
phase of treatment (when an injection is given
every 4 weeks for 3 injections) and every
5.8 weeks in the second year of treatment.
There are many weaknesses in this work
including its retrospective nature and non-
standardized approach to treatment and
limited sample size; however there are also
several strengths including the report of ‘‘real-
life’’ outcomes from patients treated at a large
tertiary referral center.
CONCLUSION
These data suggest that missed hospital visits
may be a relatively common occurrence in AMD
treatment clinics, but good outcomes of
treatment can be achieved over 2 years if
patients are reviewed on average six times in
the first year after an initial loading phase of
three injections (one injection a month for
3 months) and nine times in the second year of
treatment.
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